Chemistry:Enavogliflozin
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | DWP16001 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H27ClO6 |
| Molar mass | 446.92 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Enavogliflozin (DWP16001) is an experimental selective SLC5A2 and SGLT2 inhibitor developed to treat diabetes and obesity.[1][2][3][4][5]
References
- ↑ Hwang, Jun Gi; Lee, SeungHwan; Huh, Wan; Han, Jumi; Oh, Jaeseong; Jang, In-Jin; Yu, Kyung-Sang (September 2022). "Dose-dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter-2 inhibitor, in healthy subjects". British Journal of Clinical Pharmacology 88 (9): 4100–4110. doi:10.1111/bcp.15348. PMID 35395697.
- ↑ Kim, Ju-Hyun; Kim, Dong Kyun; Choi, Won-Gu; Ji, Hye-Young; Choi, Ji-Soo; Song, Im-Sook; Lee, Sangkyu; Lee, Hye Suk (11 September 2020). "In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes". Pharmaceutics 12 (9): 865. doi:10.3390/pharmaceutics12090865. PMID 32932946.
- ↑ Kim, Byungwook; Huh, Ki Young; Hwang, Jun Gi; Nah, JaeJin; Huh, Wan; Cho, Jae Min; Jang, In-Jin; Yu, Kyung-Sang et al. (April 2023). "Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium–glucose cotransporter 2 inhibitor and metformin in healthy subjects". British Journal of Clinical Pharmacology 89 (4): 1462–1470. doi:10.1111/bcp.15613. PMID 36422809.
- ↑ Rhee, Beomseok; Mahbubur, Rahman Md; Jin, Changfan; Choi, Ji-Soo; Lim, Hyun-Woo; Huh, Wan; Park, Joon Seok; Han, Jumi et al. (December 2022). "Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs". BMC Veterinary Research 18 (1): 237. doi:10.1186/s12917-022-03324-2. PMID 35733159.
- ↑ Yoon, Sukyong; Park, Min Soo; Jin, Byung Hak; Shin, Hyobin; Na, Jaejin; Huh, Wan; Kim, Choon Ok (3 July 2023). "Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects". Expert Opinion on Drug Metabolism & Toxicology 19 (7): 479–485. doi:10.1080/17425255.2023.2249397. PMID 37593838.
 |  |
